kristoff@GENBANK.BIO.NET (Dave Kristofferson) (05/01/91)
NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution. The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs. There are quite a few lengthy RFAs in
this issue so this will be sent out over the course of severla days to
prevent mail overload on some systems. -D.K.
----------------------------------------------------------------------
NIH GUIDE - Vol. 20, No. 18, May 3, 1991
$$INDEX BEGIN **********************************************************
NOTICES
$$INDEX N1 *************************************************************
REVIEW PROCEDURES FOR PROGRAM PROJECT GRANT APPLICATIONS
National Institute of Child Health and Human Development
Index: CHILD HEALTH, HUMAN DEVELOPMENT
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$INDEX R1 *************************************************************
EVALUATION OF NIH IMPLEMENTATION OF SECTION 491 OF THE PUBLIC HEALTH
SERVICE ACT, MANDATING A PROGRAM OF PROTECTION FOR RESEARCH SUBJECTS
(RFP)
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
$$INDEX R2 *************************************************************
PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER SCREENING TRIAL -
SCREENING CENTERS (RFP)
National Cancer Institute
Index: CANCER
$$INDEX R3 08/06/91 ****************************************************
ADULT AIDS CLINICAL TRIALS UNITS (RFA AI-91-07)
National Institute of Allergy and Infectious Diseases
Index: ALLERGY, INFECTIOUS DISEASES
$$INDEX R4 09/06/91 ****************************************************
COOPERATIVE NETWORK FOR MOLECULAR GENETIC AND CYTOGENETIC STUDIES OF
PROSTATE CANCER (RFA CA-91-10)
National Cancer Institute
Index: CANCER
$$INDEX R5 06/24/91 ****************************************************
STATE SERVICE SYSTEMS IMPROVEMENT THROUGH CONSUMER AND FAMILY SUPPORT
ACTIVITIES (RFA MH-91-13)
National Institute of Mental Health
Index: MENTAL HEALTH
$$INDEX R6 07/31/91 ****************************************************
COOPERATIVE NETWORK FOR EVALUATION OF PROGNOSTIC MARKERS OF URINARY
BLADDER CANCER (RFA CA-91-09)
National Cancer Institute
Index: CANCER
$$INDEX R7 06/21/91 ****************************************************
ADAMHA SMALL INSTRUMENTATION PROGRAM (RFA AA-91-03)
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, MENTAL HEALTH
$$INDEX END ************************************************************
NOTICES
$$N1 BEGIN *************************************************************
REVIEW PROCEDURES FOR PROGRAM PROJECT GRANT APPLICATIONS
P.T. 34; K.W. 1014006
National Institute of Child Health and Human Development
Effective for the June 1, 1991 receipt date, program project (P01)
applications assigned to the National Institute of Child Health and
Human Development (NICHD) will no longer be routinely site-visited.
These applications will be considered by the relevant Initial Review
Group (IRG) without interaction with the applicant. The IRG will have
the option of deferring an application for a site visit, although this
will be the exception rather than standard practice.
As a result of this change, NICHD P01 applicants must ensure that the
description of the proposed research for each component project/core
facility is thorough and complete (not to exceed 20 pages), permitting
direct evaluation by the reviewers.
Unless otherwise indicated, NICHD Center Core (P30) Grant and
Specialized Center (P50) Grant applications will continue to receive
site visits as a part of the review process.
Programatic questions about this announcement should be directed to:
Laurance S. Johnston, Ph.D.
Acting Director, Division of Scientific Review
NICHD/NIH
Executive Plaza North, Room 520
Bethesda, MD 20892
Telephone: (301) 496-1696
Grants management questions should be directed to:
Donald Clark
Chief, Office of Grants and Contracts
National Institute of Child Health and Human Development
Executive Plaza North, Room 501
Bethesda, MD 20892
Telephone: (301) 496-5001
$$N1 END ***************************************************************
NOTICES OF AVAILABILITY (RFPs AND RFAs)
$$R1 BEGIN NIH-OD-91-12 ************************************************
EVALUATION OF NIH IMPLEMENTATION OF SECTION 491 OF THE
PUBLIC HEALTH SERVICE ACT, MANDATING A PROGRAM OF PROTECTION
FOR RESEARCH SUBJECTS
RFP AVAILABLE: NIH-OD-91-12
P.T. 34; K.W. 0783005
National Institutes of Health
The Office of Extramural Programs, Office of Extramural
Research, Office of the Director, National Institutes of
Health, has a requirement to evaluate the national program of
protection for research subjects at institutions engaged in
research funded by the Department of Health and Human
Services pursuant to Section 491 of the PHS Act. This
evaluation will examine the extent to which the program is
meeting this objective while continuing to facilitate needed
research to improve the nation's health. Preliminary
considerations suggest four broad categories of measurement:
outcome measures focusing on adequacy of consent
procedures, risk assessment and subject selection; output
measures, including workload and caseload measures from
institutional records; process measures exploring
variations in institutional procedures and deployment of the
program in new settings and in use of innovative
interventions; and resource measures of personnel, time, effort
and costs. The contractor must have the professional
capabilities and facilities to evaluate government programs
of national scope and comparable complexity with major
implications for Federal health sciences policy, government-
university relations, and the broad public. The results of
the study will be the basis for recommendations to ensure
responsiveness to rapidly changing research opportunities
while maintaining appropriate safeguards for individuals
involved as subjects of research. It is expected that the
contract will have a two- (2) year period of performance.
Any responsible offeror may submit a proposal that will be
considered by the Government.
The issuance date of the RFP will be on or about May 31,
1991, and proposals will be due by the close of business 50
days after issuance.
Requests for the RFP must be directed to:
Valerie Pickett
Research Contracts Branch
Division of Contracts and Grants
Office of the Director
National Institutes of Health
Building 31, Room 1B44
9000 Rockville Pike
Bethesda, MD 20892
$$R1 END ***************************************************************
$$R2 BEGIN NCI-CN-15342-04 *********************************************
PROSTATE, LUNG, COLORECTAL, AND OVARIAN CANCER
SCREENING TRIAL - SCREENING CENTERS
RFP AVAILABLE: NCI-CN-15342-04
P.T. 34; K.W. 0715035, 0745020, 0755015
National Cancer Institute
The National Cancer Institute (NCI), Division of Cancer Prevention
and Control, Early Detection Branch, is interested in
soliciting proposals from organizations for Screening
Centers for the Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial. Up to fifteen (15) screening
Centers will be established, each recruiting no less than
5,000 subjects and 5,000 controls to the trial. A total of
148,000 men and women will be recruited to the trial in
approximately equal numbers. Female subjects will be
screened for colorectal, lung, and ovarian cancers. Male
subjects will be screened for colorectal, lung, and prostate
cancer. Screening will be annually for four years for
prostate, lung, and ovarian cancers and only in years one
and three for colorectal cancer. Subjects and controls will
be followed for at least ten years. A Coordinating and Data
Management Center will develop and maintain systems and
procedures for biomedical data management, study
coordination, statistical analysis, and report writing. The
NCI has selected the cancer sites and screening modalities.
Screening Centers, in cooperation with the NCI, will develop
screening logistics and diagnostic protocols. A
pre-proposal conference will be held and the date will be
specified in the Request for Proposals (RFP).
Requests for this RFP must be in writing and
reference RFP No. NCI-CN-15342-04. The RFP will be
available approximately April 25, 1991 and will be due
approximately June 10, 1991.
Copies of the RFP may be obtained by sending a written
request to:
Mr. Christopher B. Myers, Contract Specialist
National Institutes of Health
National Cancer Institute
Research Contracts Branch, PCCS
Executive Plaza South, Room 635
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-8603
$$R2 END ***************************************************************
$$R3 BEGIN AI-91-07 FULL-TEXT ******************************************
ADULT AIDS CLINICAL TRIALS UNITS
RFA AVAILABLE: AI-91-07
P.T. 34; K.W. 0715008, 0755015
National Institute of Allergy and Infectious Diseases
Letter of Intent Receipt Date: June 5, 1991
Preapplication Meetings: June 3, 4 and 5, 1991
Application Receipt Date: August 6, 1991
BACKGROUND
The National Institute of Allergy and Infectious Diseases
(NIAID) announces the availability of a Request for
Applications (RFA) for AIDS Clinical Trials Units (ACTUs). The
purpose of this RFA is to recompete the adult component of
the AIDS Clinical Trial Group (ACTG) by soliciting
applications from existing ACTUs and from new applicants.
This initiative will utilize the cooperative agreement.
The adult component of the ACTG is a network of
32 domestic biomedical research institutions that, in
aggregate, has the capabilities to develop new therapeutic
interventions from initial clinical trials in human subjects
to their final approval by the Food and Drug Administration.
The research objectives of the ACTG are to evaluate the
safety and efficacy of therapeutic interventions for the
treatment of Human Immunodeficiency Virus (HIV) infection,
acquired immunodeficiency syndrome (AIDS), and associated
opportunistic conditions.
HEALTHY PEOPLE 2000
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
Healthy People 2000, a PHS-led national activity for
setting priority areas. This RFA, Recompetition of the
Adult AIDS Clinical Trials Units, is related to the priority
area of HIV infection.
Potential applicants may obtain a copy of "Healthy People 2000"
(Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000"
(Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (telephone 202-783-3238).
OBJECTIVES
It is the intent of the recompetition to maintain a
cooperative network of adult ACTUs that has the capability
to conduct all phases of therapeutic clinical evaluation to
identify new therapies and to facilitate the transfer of
interventions from the research setting to routine patient
care. Emphasis will be placed on the inclusion of women,
minorities and substance abusers in the clinical studies so
that the patients participating in the clinical trials
network reflect the demographic features of the national HIV
epidemic. This network will be composed of investigators
from a variety of disciplines with demonstrated expertise
and experience in conducting clinical trials especially
among HIV infected patients. The research objectives will
be accomplished through the development of protocols,
accrual of patients to ACTG protocols, submission, analysis
and publication of data, and by participation of the ACTU
investigators in ACTG committees. The research agenda and
priorities will be established by the ACTG Executive
Committee whose members include the Associate Director of
the Treatment Research Program, DAIDS. Scientific areas of
highest priority include antiretroviral therapy and
treatment of opportunistic infections associated with HIV
infection. Studies of HIV-associated malignancies and
neurological complications will also be emphasized. The
ACTG committees (Scientific, Resource, and Executive) are
composed of investigators from the ACTUs, a NIAID staff
representative, and representatives from patient advocacy
groups. In order to achieve these objectives, supplementary
resources will continue to be provided to the ACTU Principal
Investigators by the NIAID through other funding mechanisms
and include: (1) a Statistical and Data Analysis Center that
assists in protocol design and functions as a central data
management center, (2) an Operations Office that provides
technical and logistical support for the development and
implementation of protocols, (3) Clinical Site Monitoring to
ensure the quality of data and conformance with regulatory
requirements, and (4) a Clinical Research Products Repository
that provides for the receipt, inventory, and distribution of
investigational drugs.
The RFA contains information related to
both required and optional components. All applicants must
apply for the ACTU clinical core funding to be eligible to
apply for optional components. The clinical core funding
will provide the resources required to maintain an
infrastructure sufficient to accrue an agreed upon minimum
annual number of new patients on to protocols. The clinical
core funds also will support laboratory costs for protocol
mandated immunophenotyping. Applicants for the ACTU
clinical core funding will be eligible to apply for optional
components that include: (1) pediatric clinical trials
[limited to adult ACTUs that have an existing pediatric
component], (2) virology core laboratory support for
protocol mandated testing, (3) pharmacology core laboratory
support for protocol mandated testing, (4) developmental
research in virology [limited to applicants who apply for
and are awarded funds for (2)], (5) developmental research
in pharmacology [limited to applicants who apply for and are
awarded funds for (3)], (6) developmental research in
immunology, and (7) developmental research in other areas of
microbiology. An applicant must receive an award for the
ACTU clinical core to be eligible for funding of the
optional components. However, funding priorities for the
optional components will be established independent of the
priorities for the ACTU clinical core awards. Funding
priorities for the ACTU clinical core will not be affected
by the presence or absence of optional components.
SPECIAL INSTRUCTIONS FOR THE INCLUSION OF WOMEN AND
MINORITIES IN CLINICAL RESEARCH STUDIES
The following is a brief statement of the NIH and ADAMHA
policy regarding the inclusion of women and minorities in
study populations. The inclusion of women and minorities
should be addressed in applications submitted in response to
this RFA.
For projects involving clinical research, NIH requires
applicants to give special attention to the inclusion
of women and minorities in study populations. If
women or minorities are not included or adequately
represented in the study populations for clinical
studies, a specific justification must be provided.
Application without such documentation will not be
accepted for review.
MECHANISM OF SUPPORT
Awards will be made as cooperative agreements (UO1). The
cooperative agreement funding instrument differs from the
traditional research grant in that the Government awarding
component (NIAID) anticipates substantial programmatic
involvement during the performance. The nature of NIAID
staff assistance is described in the RFA. However,
applicants must define their own objectives in accord with
individual interests and approaches to conducting the
research. The NIAID anticipates that $48,000,000 will be
available for the initial year of funding applications in
response to this RFA and that approximately 20-25
applications will be funded. The award of grants pursuant
to this RFA is contingent on the continuing availability of
funds for this purpose and on the receipt of a sufficient
number of applications of high scientific merit.
APPLICATION SUBMISSION
Eligibility: Any domestic university, medical college,
hospital, or other clinical research institution is eligible.
Under the terms of this RFA, new applicants and established
adult ACTUs are invited to apply. Only domestic
organizations are eligible to apply and the application may
not include an international component.
Letter of Intent: Prospective applicants are asked to
submit, by June 5, 1991, a letter of intent that includes a
descriptive title and description of the proposed research
not to exceed three pages. The letter of intent is
requested to provide an indication of the number and scope
of applications to be received and to promote early
interaction between NIAID staff and the applicant. The
letter of intent does not commit the sender to submit an
application, nor is it a requirement for submission of an
application.
Submission: The research grant application form PHS 398
(rev. 10/88, reprinted 9/89) must be used in applying. These
forms are available at most institutional business offices and
from the Division of Research Grants, National Institutes of
Health, Westwood Building, Room 449, 5333 Westbard Avenue,
Bethesda, MD 20892. To identify responses to this
announcement under Item 2 on page 1 of the grant application,
check 'yes' and include the title and number of the RFA.
The RFA label in the form PHS 398 must be affixed to the
bottom of face page of the original signed application.
Failure to do so could result in delayed processing of the
application so that it may not reach the review committee in
time for review. Incomplete and nonresponsive applications
will be returned to the applicant without review.
REVIEW PROCEDURES
Comprehensive evaluation of the applications will be
conducted by a Special Review Committee (SRC) consisting
primarily of non-Federal scientific experts. The adult
component (Part A) and pediatric component (Part B, if
present) will be evaluated and scored based on the
scientific merit at one SRC session. Optional components
will be forwarded to a second SRC for evaluation. The
priority score assigned to the application will be based on
the score received for Part A. The merit of Part B and Part
C components will be used by NIAID to guide funding
decisions with respect to these components.
APPLICATION PROCEDURES
Submit by August 6, 1991, a signed, typewritten original of the
application, and 6 exact, single-sided photocopies (including Appendix)
in one package to:
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
Submit 17 exact, single-sided photocopies
of the application in one package directly to:
Dr. Allen Stoolmiller
AIDS Review Section
NIAID/DEA/PPRB
Westwood Building, Room 3A-07
5333 Westbard Avenue
Bethesda, MD 20892
INQUIRES
The RFA is available from and
Letters of Intent are to be sent to:
F.H. Batzold, Ph.D.
Division of AIDS
National Institute of Allery and Infectious Diseases
6003 Executive Boulevard, Room 208P
Rockville, MD 20892
Telephone: (301) 496-8214
For budget questions, contact:
Ms. Mary Kirker
Chief, AIDS Grants Management Section
Grants Management Branch/NIAID
Westwood Building, Room 706
Bethesda, MD 20892
Telephone: (301) 496-7075
$$R3 END ***************************************************************
$$R4 BEGIN CA-91-10 FULL-TEXT ******************************************
COOPERATIVE NETWORK FOR MOLECULAR GENETIC AND CYTOGENETIC
STUDIES OF PROSTATE CANCER
RFA AVAILABLE: CA-91-10
P.T. 34; K.W. 0715035, 1002058, 1002004, 0413001
National Cancer Institute
Letter of Intent Receipt Date: June 10, 1991
Application Receipt Date: September 6, 1991
The Cancer Diagnosis Branch of the Division of Cancer Biology, Diagnosis
and Centers (DCBDC) at the National Cancer Institute (NCI) invites
applications for cooperative agreements from institutions capable of and
interested in participating in a cooperative network for studies of
molecular genetics and cytogenetics of prostate cancer. The goals of
this Request for Applications (RFA) are: 1) to promote collaborations
and interactions between basic scientists and clinicians in order to
advance prostate cancer research; 2) to identify genetic alterations
that may distinguish the behavior of clinically silent prostate cancer
from that of clinically evident cancer; 3) to determine whether there is
a molecular genetic basis for differences in prostate cancer incidence
between Blacks and Whites; 4) to explore the biological basis for the
striking increase in prostate cancer incidence with age. Groups
participating in the network will attempt to assess biological
differences in prostate cancer using molecular genetic and cytogenetic
approaches with the long-term goal of developing a more informative
classification system. Cooperative studies will facilitate the
application of molecular techniques to prostate cancer research through
the efficient use of prostate cancer and normal prostate tissue.
Awards will be made as cooperative agreements that
create an assistance relationship with substantial
involvement of NCI staff during the performance of the
project, as outlined in the
RFA. This mechanism is used when the NCI wishes to
stimulate investigator interest and proposes to advise or
assist in an important and opportune area of research.
Applicants will be responsible for the planning,
direction, and execution of the proposed project. It is
essential that there be good liaison between basic
scientists and clinicians. Each group responding to
this RFA must describe existing and proposed
collaboration/cooperation between basic scientist(s) and
clinician(s).
The NCI anticipates making three to five awards for project
periods of up to four years. A total of $1,000,000 is
expected to be set aside for the initial year's funding.
Although this program is provided for in the financial
plans of the NCI, the award of cooperative agreements
pursuant to this RFA is contingent on the availability of
funds appropriated for fiscal year 1992.
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
HEALTHY PEOPLE 2000, a PHS-led national activity for
setting priority areas. This RFA, "Cooperative Network
for Molecular Genetic and Cytogenetic Studies of Prostate
Cancer" is related to the priority area of cancer.
Potential applicants may obtain a copy of "Healthy People 2000"
(Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000"
(Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (telephone 202-783-3238).
For projects involving clinical research, NIH requires
applicants to give special attention to the inclusion of
women and minorities in study populations. While
inclusion of women is not relevant to this RFA, special
emphasis should be placed on the need for inclusion of
minorities, particularly blacks, who are
disproportionately affected, in studies of prostate
cancer. If minorities are not included or are
inadequately represented in the study populations for
clinical studies, a specific justification for this
exclusion or inadequate representation must be provided.
Applications without such documentation will not be
accepted for review.
This RFA is a one-time solicitation with a specified
deadline of September 6, 1991 for receipt of
applications.
A copy of the complete RFA describing the research goals
and scope, the cooperative agreement mechanism, the
review criteria, and other application requirements
is available from:
Roger L. Aamodt, Ph.D.
Program Director for Pathology/Cytology
Cancer Diagnosis Branch, DCBDC, NCI
Room 638, Executive Plaza South
6120 Executive Boulevard
Rockville, MD 20892-9904
Telelephone: (301) 496-7147
FAX: (301) 496-8656
Inquiries concerning this RFA are encouraged and should
be directed to Dr. Aamodt at the above address and
telephone number.
For fiscal and administrative matters, contact:
Robert E. Hawkins
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
EPS, Room 216
Bethesda, MD 20892
Telephone: (301) 496-7800 ext. 13
This program is described in the Catalog of Federal
Domestic Assistance No. 93.394, Cancer Detection and
Diagnosis Research. Awards are made under authorization of
the Public Health Service Act, Title IV, Part A (Public
Law 78-410 as amended: 42 USC 241) and administered under
PHS grant policies and Federal Regulations 42 CFR Part 52
and 45 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order
12372 or Health Systems Agency review.
$$R4 END ***************************************************************
$$R5 BEGIN MH-91-13 FULL-TEXT ******************************************
STATE SERVICE SYSTEMS IMPROVEMENT THROUGH CONSUMER AND
FAMILY SUPPORT ACTIVITIES
RFA AVAILABLE: MH-91-13
P.T. 34; K.W. 0730050, 0715095, 0715129, 0403004
National Institute of Mental Health
Application Receipt Date: June 24, 1991
PURPOSE
The Community Support Program (CSP) of the National Institute of Mental
Health (NIMH) is inviting applications under this Request for
Applications (RFA) to demonstrate and evaluate service system
improvement strategies that integrate consumers and family members into
the planning and provision of mental health and support services at
State and local levels.
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000", a
PHS-led national activity for setting priority areas. This RFA, "State
Service Systems Improvement Through Consumer and Family Support
Activities," is related to the priority area of mental health.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary
Report: Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, D.C. 20402-9325
(telephone 202-783-3238).
Applications are encouraged that demonstrate and
evaluate strategies that are directed toward the
following programmatic goals:
o Integrating primary consumers and family members
into State and local service delivery, systems
planning, decision-making, and research activities in
order to develop mental health and support services
that are considered responsive to consumer and family
needs and preferences;
o Improving linkages between consumer self-help and
family support groups and the formal community support,
treatment, and rehabilitation service systems;
o Increasing the effectiveness of consumers and
family members in identifying and fostering needed
system, program, and service improvements;
o Fostering participation of minority individuals in
consumer self-help and family support groups as an
element of the service delivery planning and decision
making;
o Increasing opportunities for consumer employment
within the formal service system.
POPULATION OF CONCERN
The population of concern for CSP grants includes
individuals 18 years and over with a severe and
persistent mental disorders that seriously impair
functioning in primary aspects of daily living, such as
interpersonal relations, living arrangements, and
employment. Applicants should pay attention to the
unique needs and special concerns of racial and ethnic
minorities and women.
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants
to give special attention to the inclusion of women and
minorities in study populations. If women or minorities are not
included in the study populations for clinical studies, a
specific justification for this exclusion must be provided.
Applications without such documentation will not be accepted for
review.
ELIGIBILITY
Only mental health authorities in States and
Territories that do not currently have a CSP State
Service System Improvement Demonstration Grant or are
in the final year of a CSP State Service System
Improvement Demonstration Grant for general community
support development activities are eligible to apply
for these grants. Each State and Territory may submit
only one application.
APPLICATION PROCEDURES
All applicants must use form PHS-5161 (revised 3/89).
Application kits are available from:
Grants Management Branch
National Institute of Mental Health
Parklawn Building, Room 7C-15
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4414
TERMS AND CONDITIONS OF SUPPORT
Period of Support
Support may be requested for a period of up to three years.
Annual awards will be made subject to continued
availability of funds and progress achieved.
In Fiscal Year 1991, it is estimated that approximately
$1 million will be available to support approximately
10 projects. The expected average amount of an award,
for direct costs, is estimated to be $100,000 per year.
However, the amount of funding available will depend on
appropriated funds and program priorities at the time
of award.
Allowable Costs
Applicants must include the following agreement in
their applications: "(Applicant) agrees that not more
than 10 percent of any resultant grant award will be
expended for administrative purposes."
Grants are intended to assist in meeting the costs of
planning, developing, and implementing activities to
support attainment of the project objectives. Grant
funds are to be additive, not substitutive; they are
not to be used to replace existing resources.
Grant funds may be used for expenses clearly related
and necessary to carry out the proposed project,
including both direct and indirect costs that are
specifically identified with the proposed project.
INQUIRIES
Applicants are encouraged to contact Institute staff
before applying for an award:
Neal Brown, Chief
Community Support Section
System Development and Community Support Branch
Division of Applied and Services Research
National Institute of Mental Health
Parklawn Building, Room 11C-22
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-3653
Inquiries pertaining to grants management should be
directed to:
Steven Hudak
Chief, Grants Management Section
Grants Management Branch
National Institute of Mental Health
Parklawn Building, Room 7C-23
Rockville, MD 20857
Telephone: (301) 443-4456
$$R5 END ***************************************************************
$$R6 BEGIN CA-91-09 FULL-TEXT ******************************************
COOPERATIVE NETWORK FOR EVALUATION OF PROGNOSTIC MARKERS OF
URINARY BLADDER CANCER
RFA AVAILABLE: CA-91-09
P.T. 34; K.W. 0715035, 0785220, 0765033
National Cancer Institute
Letter of Intent Receipt Date: May 31, 1991
Application Receipt Date: July 31, 1991
The Cancer Diagnosis Branch of the Division of Cancer Biology, Diagnosis
and Centers at the National Cancer Institute invites applications for
cooperative agreements from institutions capable of and interested in
participating in the "Cooperative Network for Evaluation of Prognostic
Markers of Urinary Bladder Cancer." The objective of this Request for
Applications (RFA) is to invite applications for cooperative agreements
to support a network of laboratories to cooperatively evaluate promising
diagnostic and prognostic markers of urinary bladder cancer. The
network will perform collaborative studies requiring expertise in
urology, pathology, and/or basic cancer biology to evaluate appropriate
quantifiable markers of urinary bladder cancer and to define relevant
clinical applications. This network will continue and expand the
collaborative studies of urinary bladder cancer markers currently
supported by the "Marker Network for Bladder Cancer."
Awards will be made as cooperative agreements that
create an assistance relationship with substantial NCI
programmatic involvement with the recipients during the
performance of the project, as outlined in this
RFA. The cooperative agreement
mechanism is used when the NCI wishes to stimulate
investigator interest and proposes to assist in an
important and opportune area of research. Applicants
will be responsible for the planning, direction, and
execution of the proposed project.
The NCI anticipates making four to six awards for project
periods of up to four years. A total of $950,000 is
expected to be set aside for funding these activities in
the initial year. Although this project is provided for
in the financial plans of the NCI, the award of
cooperative agreements pursuant to this RFA is contingent
on the availability of funds appropriated in fiscal year
1992.
The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of
"Healthy People 2000," a PHS-led national activity for
setting priority areas. This RFA, "Cooperative Network
for Evaluation of Prognostic Markers of Urinary Bladder
Cancer," is related to the priority area of cancer.
Potential applicants may obtain a copy of "Healthy People 2000"
(Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000"
(Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office,
Washington, D.C. 20402-9325 (telephone 202-783-3238).
For projects involving clinical research, NIH requires
applicants to give special attention to the inclusion of
women and minorities in study populations. If women or
minorities are not included or are inadequately
represented in the study populations for clinical
studies, a specific justification for this exclusion or
inadequate representation must be provided. Applications
without such documentation will not be accepted for
review.
This RFA is a one-time solicitation with a specified
deadline of July 31, 1991 for receipt of applications.
A copy of the complete RFA describing the research goals
and scope, the cooperative agreement mechanism, the
review criteria, and other application requirements
is available from:
Roger L. Aamodt Ph.D.
Program Director for Pathology and Cytology
Cancer Diagnosis Branch, DCBDC, NCI
Executive Plaza South, Room 638
6120 Executive Boulevard
Rockville, MD 20892-9904
Telephone: (301) 496-7147
FAX: (301) 496-8656
Inquiries concerning this RFA or the activities of the
currently funded marker network are encouraged and should
be directed to Dr. Roger L. Aamodt at the above address
or telephone or FAX number.
For fiscal and administrative matters, contact:
Robert E. Hawkins
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
EPS, Room 216
Bethesda, MD 20892
Telephone: (301) 496-7800 ext. 13
This program is described in the Catalog of Federal
Domestic Assistance No. 93.394, Cancer Detection and
Diagnosis Research. Awards are made under authorization of
the Public Health Service Act, Title IV, Part A (Public
Law 78-410 as amended: 42 USC 241) and administered under
PHS grant policies and Federal Regulations 42 CFR Part 52
and 45 CFR Part 74. This program is not subject to the
intergovernmental review requirements of Executive Order
12372 or Health Systems Agency review.
$$R6 END ***************************************************************
$$R7 BEGIN AA-91-03 ****************************************************
ADAMHA SMALL INSTRUMENTATION PROGRAM
RFA: AA-91-03
P.T. 34; K.W. 0735000
Alcohol, Drug Abuse, and Mental Health Administration
Letter of Intent Receipt Date: May 20, 1991
Application Receipt Date, June 21, 1991
The Alcohol, Drug Abuse, and Mental Health Administration
(ADAMHA) is announcing the third year of the ADAMHA Small
Instrumentation Program (ASIP). This program was reauthorized by
Congress for FY 1991 in Section 501(m) of the Public Health
Service Act, as added to by P.L. 100-690, in response to
findings that much of the research instrumentation in the
Nation's principal universities is either obsolete or poorly
maintained. These findings, documented in several reports,
identified the need for upgrading equipment currently in use.
The most significant need was for relatively low-cost pieces
of equipment. To address this problem, ADAMHA established
the Small Instrumentation Program in FY 1989. Awards are
made under authority of Titles III and of the PHS Act as
amended. Funds will be provided to research-intensive
institutions currently receiving ADAMHA research support.
The ASIP is not intended to replace requests for equipment in
applications for individual research projects. Rather, it is
intended to help fund items of equipment that are difficult
to justify within the context of an individual research
project but that will upgrade the institution's research
infrastructure.
The ADAMHA program has a similar purpose to the National
Institutes of Health Small Instrumentation Program but will
operate separately and under slightly different guidelines
because of differences in the infrastructure support
mechanisms available to the two agencies.
The ADAMHA program will be funded in FY 1991 at $2,402,000.
The program provides awards ranging from $20,000 to $60,000
to eligible institutions. Eligible institutions are those
that had five or more active ADAMHA research grants awarded
in FY 1990. The awards must be from the following types of
research mechanisms: R01, R03, R29, and R37. The amount for
which an institution may apply was calculated by a formula
based on the $2,402,000 available for the program this year
and on the number of ADAMHA-sponsored awards in the eligible
mechanisms at an institution. Each eligible institution
may submit ONLY ONE application that incorporates all
appropriate equipment requests from that institution. Thus,
it is essential that institutional officials publicize the
availability of ASIP funds so that ADAMHA-supported
investigators in need of small research instruments are
provided the opportunity to indicate their needs for such
equipment to the appropriate institutional official.
The equipment requested must be available for use by more
than one project either currently or in the future. The
primary user(s) of the equipment must be one or more
Principal Investigators of active ADAMHA-supported research
grants, and the specific projects must be cited in the
application. No indirect costs will be provided and there
will be no future year funding commitment. The requested
funds may be for full or partial support of one or more
pieces of equipment In no case, however, can the total purchase
price of a requested piece of equipment be less than $5,000
or more than $100,000 regardless of the source(s) of funding.
If the total dollar amount of proposed eguipment purchases
exceeds the amount for which the institution is eligible, a
statement must be submitted indicating the
institution will provide the difference. Support from this
program cannot be used to purchase items exceeding $100,000
in cost even if costs are shared. The equipment purchased
must be the same as that specified in the ASlP application.
Applications must be received by June 21, 1991, and letters of
intent should be received by May 20, 1991. Detailed
application procedures have been sent to eligible
institutions. Applications will be peer reviewed by a single
ADAMHA-wide committee. The review criteria are: Degree of
adherence to the terms of the letter of eligibility and
adequacy of the justification provided for the equipment
requested. The reviewers will determine whether the
application is recommended for approval; no priority scores
will be voted. Applications will be assigned to individual
ADAMHA Institutes for consideration by their National
Advisory Councils and for funding. The Institutes expect to
make the awards in September.
Ouestions concerning this program may be directed to any of
the following persons:
Dr. Charles Sharp
Division of Preclinical Research
National Institute on Drug Abuse
Room 10A-31
Telephone: (301) 443-6300
Mr. James Moynihan
Division of Basic Brain and Behavioral Sciences
National lnstitute of Mental Health
Room 11-95
Telephone: (301) 443-3107
Dr. Leslie Isaki
Division of Basic Research
National Institute on Alcohol Abuse and Alcoholism
Room 16C-05
Telephone: (301) 443-4223
Grants Management Contact:
Elsie M. Fleming
Chief, Management Review and Assistance Section
National Institute on Alcohol Abuse and Alcoholism
Room 16-86
5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 443-4703
$$R7 END ***************************************************************
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS
THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.
APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO
FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE
ADDRESS FOR THE WESTWOOD BUILDING IS:
5333 Westbard Avenue
Bethesda, Maryland 20816
FULL TEXT OF RFAs FOR ONLINE ACCESS